Home/Stelexis Therapeutics/Rossitza Alargova, Ph.D.

RA

Rossitza Alargova, Ph.D.

Head of CMC

Stelexis Therapeutics

Therapeutic Areas

Hematological Cancers Inflammatory & Immunological Diseases

Stelexis Therapeutics Pipeline

Drug	Indication	Phase
Eganelisib	Higher Risk-MDS and AML	Phase 1
STLX-2012	Lower Risk-MDS and CMML	Pre-IND to Early Clinical

Leadership Team at Stelexis Therapeutics

Manuel Aivado, M.D., Ph.D.

President and Chief Executive Officer

Eric Feldman, M.D.

Chief Medical Officer

View full Stelexis Therapeutics profile